MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $324,000 Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. trimmed its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 66.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,374 shares of the company's stock after selling 55,508 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in Roivant Sciences were worth $324,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the company. Barclays PLC raised its position in Roivant Sciences by 19.7% during the third quarter. Barclays PLC now owns 459,521 shares of the company's stock valued at $5,302,000 after acquiring an additional 75,609 shares in the last quarter. Blue Trust Inc. raised its holdings in shares of Roivant Sciences by 550.1% during the 4th quarter. Blue Trust Inc. now owns 7,879 shares of the company's stock valued at $91,000 after purchasing an additional 6,667 shares in the last quarter. KBC Group NV boosted its holdings in Roivant Sciences by 58.2% in the fourth quarter. KBC Group NV now owns 15,874 shares of the company's stock worth $188,000 after purchasing an additional 5,839 shares in the last quarter. FSA Advisors Inc. acquired a new position in Roivant Sciences during the fourth quarter worth $130,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Roivant Sciences by 8.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 154,352 shares of the company's stock valued at $1,826,000 after buying an additional 12,118 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ROIV. Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a research note on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and set a $18.00 target price on shares of Roivant Sciences in a research report on Wednesday, May 28th.

Roivant Sciences Trading Down 0.3%

Roivant Sciences stock traded down $0.03 on Wednesday, reaching $11.21. 5,089,654 shares of the stock were exchanged, compared to its average volume of 5,553,324. Roivant Sciences Ltd. has a twelve month low of $8.73 and a twelve month high of $13.06. The firm has a fifty day moving average price of $10.59 and a two-hundred day moving average price of $11.02. The stock has a market cap of $8.00 billion, a PE ratio of -74.73 and a beta of 1.23.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its quarterly earnings data on Thursday, May 29th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.15). Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. The business had revenue of $7.57 million during the quarter, compared to the consensus estimate of $62.17 million. During the same quarter in the previous year, the firm posted ($0.23) earnings per share. Equities analysts anticipate that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

Insider Transactions at Roivant Sciences

In related news, major shareholder Vivek Ramaswamy sold 273,959 shares of Roivant Sciences stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $11.47, for a total transaction of $3,142,309.73. Following the sale, the insider now directly owns 39,799,611 shares of the company's stock, valued at $456,501,538.17. This trade represents a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Eric Venker sold 315,522 shares of the company's stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $11.06, for a total value of $3,489,673.32. Following the completion of the transaction, the chief operating officer now directly owns 959,457 shares of the company's stock, valued at approximately $10,611,594.42. This trade represents a 24.75% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,223,959 shares of company stock worth $13,450,035 over the last three months. 7.90% of the stock is currently owned by insiders.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.